相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study
L. R. Molife et al.
BRITISH JOURNAL OF CANCER (2010)
被撤回的出版物: Molecular Analysis of Non-Small Cell Lung Cancer Identifies Subsets with Different Sensitivity to Insulin-like Growth Factor I Receptor Inhibition (Retracted article. See vol. 20, pg. 3358, 2014)
Antonio Gualberto et al.
CLINICAL CANCER RESEARCH (2010)
Targeting Insulin-Like Growth Factor Signaling: Rational Combination Strategies
David Olmos et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab(CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study
David Olmos et al.
LANCET ONCOLOGY (2010)
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy
Danielle B. Ulanet et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
被撤回的出版物: Phase II Study of the Anti-Insulin-Like Growth Factor Type 1 Receptor Antibody CP-751,871 in Combination With Paclitaxel and Carboplatin in Previously Untreated, Locally Advanced, or Metastatic Non-Small-Cell Lung Cancer (Retracted article. See vol. 30, pg. 4179, 2012)
Daniel D. Karp et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Safety, Pharmacokinetics, and Pharmacodynamics of the Insulin-Like Growth Factor Type 1 Receptor Inhibitor Figitumumab (CP-751,871) in Combination with Paclitaxel and Carboplatin
Daniel D. Karp et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma
Martha Q. Lacy et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells totreatment with gefitinib
Floriana Morgillo et al.
CLINICAL CANCER RESEARCH (2007)
The prognostic significance of pretreatment plasma levels of insulin-like growth factor (IGF)-1, IGF-2, and IGF binding protein-3 in patients with advanced non-small cell lung cancer
Ji-Youn Han et al.
LUNG CANCER (2006)
EGFR mutations in lung cancer:: Correlation with clinical response to gefitinib therapy
JG Paez et al.
SCIENCE (2004)
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib
TJ Lynch et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
